middle.news

How Anatara Lifesciences’ Anti-Obesity Compound AOC Is Shaping Its Future

1:24pm on Wednesday 25th of February, 2026 AEDT Healthcare
Read Story

How Anatara Lifesciences’ Anti-Obesity Compound AOC Is Shaping Its Future

1:24pm on Wednesday 25th of February, 2026 AEDT
Key Points
  • Net loss narrowed to $515,000 from $1.16 million a year earlier
  • Anti-Obesity Project’s compound AOC shows significant weight control effects in pre-clinical studies
  • GaRP Phase II trial demonstrates symptom improvements in IBS patients
  • Completed $1.2 million capital raising, boosting cash reserves to $1.08 million
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about ANATARA LIFESCIENCES (ASX:ANR)
OPEN ARTICLE